Emergent Biosolutions, Inc. (NYSE:EBS) Director Ronald Richard sold 23,681 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $45.02, for a total transaction of $1,066,118.62. Following the completion of the sale, the director now owns 47,091 shares in the company, valued at approximately $2,120,036.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Ronald Richard also recently made the following trade(s):

  • On Wednesday, September 27th, Ronald Richard sold 1,266 shares of Emergent Biosolutions stock. The shares were sold at an average price of $40.00, for a total transaction of $50,640.00.
  • On Thursday, September 28th, Ronald Richard sold 22,415 shares of Emergent Biosolutions stock. The shares were sold at an average price of $40.00, for a total transaction of $896,600.00.

Shares of Emergent Biosolutions, Inc. (NYSE EBS) traded up $1.36 during trading hours on Wednesday, hitting $45.48. 380,800 shares of the stock were exchanged, compared to its average volume of 345,530. The firm has a market capitalization of $1,826.36, a price-to-earnings ratio of 23.34, a PEG ratio of 1.22 and a beta of 1.24. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions, Inc. has a 52 week low of $27.94 and a 52 week high of $45.81.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.32. The company had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. Emergent Biosolutions’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.56 earnings per share. research analysts anticipate that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Emergent Biosolutions by 0.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,224,198 shares of the biopharmaceutical company’s stock worth $89,968,000 after purchasing an additional 18,486 shares during the period. Aberdeen Asset Management PLC UK raised its stake in Emergent Biosolutions by 7.3% during the second quarter. Aberdeen Asset Management PLC UK now owns 1,737,470 shares of the biopharmaceutical company’s stock worth $58,918,000 after buying an additional 118,894 shares during the last quarter. Royal Bank of Canada raised its stake in Emergent Biosolutions by 2.1% during the second quarter. Royal Bank of Canada now owns 958,568 shares of the biopharmaceutical company’s stock worth $32,505,000 after buying an additional 19,833 shares during the last quarter. Northern Trust Corp raised its stake in Emergent Biosolutions by 47.2% during the second quarter. Northern Trust Corp now owns 906,731 shares of the biopharmaceutical company’s stock worth $30,747,000 after buying an additional 290,863 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Emergent Biosolutions by 16.7% during the second quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock worth $27,820,000 after buying an additional 117,700 shares during the last quarter. Institutional investors own 92.70% of the company’s stock.

A number of analysts have weighed in on EBS shares. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research report on Wednesday, October 25th. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $46.00.

WARNING: “Insider Selling: Emergent Biosolutions, Inc. (EBS) Director Sells 23,681 Shares of Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/13/insider-selling-emergent-biosolutions-inc-ebs-director-sells-23681-shares-of-stock.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.